Understanding the Market | IMMUNEONCO-B rises over 5% as Treg cell therapy attracts attention; the company is actively advancing the clinical development of TaiZesumab
I'm PortAI, I can summarize articles.
IMMUNEONCO-B's stock price rose more than 5% in the morning, reaching HKD 11.47, with a trading volume of HKD 40.4765 million. The company is actively advancing the clinical development of the next-generation CTLA-4 antibody, Tezspire, aiming to exert anti-tumor efficacy by eliminating regulatory T cells (Treg cells) in the tumor microenvironment. The research and development of this drug is closely related to the findings of Nobel Prize winners in the field of immune tolerance mechanisms
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments